During the last decades, therapy based on blockade of PD‐1/PD‐L1 and/or CTLA‐4 has had a remarkable impact on survival in many cancers, but the effect in hematological malignancies such as AML has been limited.5 The gene discussed is CTLA4; the disease is cancer.